<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="68756">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01828840</url>
  </required_header>
  <id_info>
    <org_study_id>0080-10-HMO</org_study_id>
    <nct_id>NCT01828840</nct_id>
  </id_info>
  <brief_title>A Prospective Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia</brief_title>
  <official_title>A Prospective Double Blind Randomized Comparison of Methadone, Fentanyl, and Morphine for Post-laparotomy Epidural Analgesia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hadassah Medical Organization</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hadassah Medical Organization</source>
  <oversight_info>
    <authority>Israel: Ministry of Health</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current study aim is to compare between the opioids morphine, fentanyl and methadone in
      terms of efficacy and side effects profile when administered epidurally for pain management
      after laparotomies. Intravenous morphine will also be used. The outcomes of that method will
      be compared to those obtained using epidurally administered opioids, as this is another
      commonly used postoperative pain relief method.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>April 2013</start_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Variable stimuli, fixed response: measurement of pain tolerance by gradual increase of temperature (quantitative sensory testing (QST))as compared to baseline</measure>
    <time_frame>72 hours post operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Fixed stimuli, variable response: measurement of reaction to fixed temperature by visual analog scale (VAS) as well as Variable stimuli, variable response (electrical stimuli)as compared to baseline.</measure>
    <time_frame>72 hours post operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>patient controlled epidural analgesia (PCEI)/patient controlled analgesia (PCA)dose frequency as compared to baseline</measure>
    <time_frame>72 hours post operatively</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measurement of  opioid concentration in plasma as compared to baseline</measure>
    <time_frame>Baseline, 4 hours post surgery and twice daily for 72 hours starting 18-24 hours post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pupillometry as compared to baseline</measure>
    <time_frame>Baseline and twice daily for 72 hours starting 18-24 hours post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Respiratory rate as compared to baseline</measure>
    <time_frame>Baseline, 4 hours post surgery and twice daily for 72 hours starting 18-24 hours post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nasal capnography at rest as compared to baseline</measure>
    <time_frame>Baseline and twice daily for 72 hours starting 18-24 hours post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Report of adverse effects' severity as compared to baseline</measure>
    <time_frame>Baseline, 4 hours post surgery and twice daily for 72 hours starting 18-24 hours post surgery</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Report of pain severity- at rest, cough and deep breathing as compared to baseline</measure>
    <time_frame>Baseline, 4 hours post surgery and twice daily for 72 hours starting 18-24 hours post surgery</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Post Laparotomy Pain Treatment</condition>
  <arm_group>
    <arm_group_label>morphine, epidural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Epidurally administrated morphine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>fentanyl, epidural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epidurally administrated fentanyl</description>
  </arm_group>
  <arm_group>
    <arm_group_label>methadone, epidural</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>epidurally administrated methadone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>morphine, intervenous</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>intravenously administrated morphine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epidural morphine via PCEA</intervention_name>
    <arm_group_label>morphine, epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epidural fentanyl via PCEA</intervention_name>
    <arm_group_label>fentanyl, epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epidural methadone via PCEA</intervention_name>
    <arm_group_label>methadone, epidural</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous morphine via PCA</intervention_name>
    <arm_group_label>morphine, intervenous</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        * Elective laparotomy

        Exclusion Criteria:

          -  Subjects with diabetes mellitus, other neurological or systemic disease associated
             with altered sensory perception

          -  Illicit drug abusers

          -  Chronic use of pain medication

          -  Inability to understand consent form

          -  Age &lt; 18

          -  Renal failure (Clcr&lt;50 ml/min)

          -  Chronic use of drugs that can alter  plasma levels and\or effect of the study drugs

          -  Corrected Q-T interval(QTc)=450msc and above

          -  Contra-indication for epidural catheter insertion

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hadas Lemberg, Phd</last_name>
    <phone>0097226777572</phone>
    <email>lhadas@hadassah.org.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hadassah Medical Organization</name>
      <address>
        <city>Jerusalem</city>
        <zip>91120</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hadas Lemberg, Phd</last_name>
      <phone>972507874098</phone>
      <email>lhadas@hadassah.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Elyad Davidson, MD</last_name>
      <phone>972507874098</phone>
      <email>Edavidson@hadassah.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>Elyad Davidson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>April 8, 2013</lastchanged_date>
  <firstreceived_date>January 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>morphine</keyword>
  <keyword>fentanyl</keyword>
  <keyword>methadone</keyword>
  <keyword>epidural</keyword>
  <keyword>intravenous</keyword>
  <keyword>pain</keyword>
  <keyword>analgesia</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fentanyl</mesh_term>
    <mesh_term>Methadone</mesh_term>
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
